article thumbnail

FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices

Fierce Healthcare

Medical devices and other innovations that make acute and on-going at-home clinical management possible are receiving a boost in attention from FDA. The Food & Drug Administration’s device center launched an initiative to promote at-home medical device development with a focus on health equity in at-home care.

FDA 71
article thumbnail

J&J lung cancer initiative will use Optellum’s ‘digital biomarker’ tech

pharmaphorum

UK-based Optellum has developed an AI-powered clinical decision support – called Virtual Nodule Clinic – that it says acts as a “digital biomarker”, looking for signs of cancer in computed tomography (CT) scans. It was approved by the FDA in March, and is starting to roll out in US hospitals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

In December 2021, the US FDA issued a cross-center draft guidance with recommendations on the use of digital health technology tools (DHTTs) to acquire data remotely from participants in clinical investigations for medical products. Table 3: Example classification of DHTs. .

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

In December 2021, the US FDA issued a cross-center draft guidance with recommendations on the use of digital health technology tools (DHTTs) to acquire data remotely from participants in clinical investigations for medical products. Table 3: Example classification of DHTs. .

article thumbnail

The Incredible Shrinking Exemption: FDA Final CDS Guidance Would Significantly Narrow the Scope of Exempt Clinical Decision Support Software Under the Cures Act

The FDA Law Blog

Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. FDA interprets the term “pattern” to mean “multiple, sequential, or repeated measurements of a signal or from a signal acquisition system.”

FDA 52